- Home
- CLDX vs INVA Comparison
CLDX vs INVA Comparison
Compare CLDX & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLDX | INVA |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2008 | 2004 |
Fundamental Metrics
Financial Performance| Metric | CLDX | INVA |
|---|---|---|
| Price | $29.45 | $20.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $43.80 | $36.60 |
| AVG Volume (30 Days) | 798.4K | ★ 869.1K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.96 |
| EPS | N/A | ★ 1.52 |
| Revenue | $2,599,000.00 | ★ $388,521,000.00 |
| Revenue This Year | N/A | $13.23 |
| Revenue Next Year | $19.70 | $8.62 |
| P/E Ratio | ★ N/A | $13.60 |
| Revenue Growth | N/A | ★ 10.14 |
| 52 Week Low | $14.40 | $16.52 |
| 52 Week High | $29.83 | $22.76 |
Technical Indicators
Market Signals| Indicator | CLDX | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 67.48 | 51.95 |
| Support Level | $25.69 | $20.44 |
| Resistance Level | $27.03 | $21.93 |
| Average True Range (ATR) | 1.32 | 0.60 |
| MACD | 0.48 | -0.21 |
| Stochastic Oscillator | 93.11 | 13.77 |
Price Performance
Historical ComparisonAbout CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.